(Q45982981)

18 December 2017

title

Antimicrobial pharmacodynamics. (English)

1 reference

18 December 2017

1 reference

Ambrose PG Jr

1

1 reference

18 December 2017

Owens RC

series ordinal

2

1 reference

18 December 2017

Grasela D

series ordinal

3

1 reference

18 December 2017

publication date

1 November 2000

1 reference

18 December 2017

Medical Clinics of North America

published in

1 reference

18 December 2017

volume

84

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

1431-1446

1 reference

18 December 2017

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Single or multiple daily doses of aminoglycosides: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Once-daily dosing of aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Fungicidal effect of amphotericin B in urine: in vitro study to assess feasibility of bladder washout for localization of site of candiduria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

The scientific status of pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Bactericidal Activity of Cephalosporins in an In Vitro Model Simulating Serum Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Clinical pharmacology: the scientific basis of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

Once-daily dosing decreases renal accumulation of gentamicin and netilmicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970296-0

10.1016/S0025-7125(05)70296-0

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

PubMed ID

11155851

1 reference

18 December 2017